Company Information
CIN
Status
Date of Incorporation
12 October 1990
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
28 August 2023
Paid Up Capital
530,900,000
Authorised Capital
600,000,000
Directors
Veerayya Chowdary Kosaraju
Director/Designated Partner
over 2 years ago
over 2 years ago
Kishore Babu Lingamneni
Director/Designated Partner
over 2 years ago
over 2 years ago
Satchandra Kiran Divi
Director/Designated Partner
over 2 years ago
over 2 years ago
Rameshbabu Venkata Nimmagadda
Director/Designated Partner
over 5 years ago
over 5 years ago
Sunaina Singh
Director/Designated Partner
over 6 years ago
over 6 years ago
Ganapaty Seru
Director/Designated Partner
about 8 years ago
about 8 years ago
Suresh Kumar Gangavarapu
Director/Designated Partner
over 24 years ago
over 24 years ago
Past Directors
Nilima Prasad Divi
Additional Director
over 8 years ago
over 8 years ago
Sridevi Surapaneni
Director
over 11 years ago
over 11 years ago
Kanteti Venkata Krishna Seshavataram
Additional Director
over 11 years ago
over 11 years ago
Ranga Rao Ravipati
Additional Director
about 13 years ago
about 13 years ago
Lakshmirajani Pilakavenkata
Company Secretary
about 19 years ago
about 19 years ago
Grandhi Venkata Rao
Director
over 24 years ago
over 24 years ago
Madhusudana Rao Divi
Whole Time Director
about 31 years ago
about 31 years ago
Nimmagadda Venkata Ramana
Director
about 31 years ago
about 31 years ago
Murali Krishna Prasad Divi
Managing Director
about 35 years ago
about 35 years ago
Patents
Resolution of the title compound to its active isomer (R)-l-(3-hydroxyphenyl)-2-methylamino ethanol with (R)- naproxen as resolving agent is reported.
(R,S)-Nicotine was resolved through diastereomeric salt formation using dibenzoyl-d- tartaric acid and dibenzoyl-l-tartaric acid to obtain enantiomerically pure (S)-nicotine and (R)-nicotine.
The present invention provides a method for preparing colorless sucralose, wherein 4,l",6"-trichloro-4,1",6" -trideoxy-galactosucrose-6-acetate containing colored impurities formed during chlorination of sucrose-6-acetate is treated with sodium hypochlorite where sodium hypochlorite acts both as a decolorizing agent...
Process for the Preparation of Pregabalin
The present invention provides a new enantioselective method of preparing (S)-3- (aminomethyl)-5-methylhexanoic acid, commonly known as pregabalin. The invention also provides new chiral intermediates useful in the production of pregabalin.
The resolution of racemic l-(4-methoxybenzyl)-octahydro-isoquinoline, a key intermediate in the synthesis of the antitussive agent dextromethorphan, is reported using (R)-2-(6-methoxy-2-naphthyl) propionic acid in good yields. The resolving agent and the undesired isomer of the octahydro- isoquinoline have been reco...
Present invention relates to isomerization of Z-lycopene in mixtures of isomers to mixtures enriched with all E-lycopene.
A process for (R,S)-nicotine is described. Condensation of 1-(but-1-enyl) pyrrolidin-2-one with nicotinic acid ester gave 1-(but-1-enyl)-3-nicotinoylpyrrolidin-2-one which on treatment with an acid and a base gave myosmine. Myosmine was converted to (R,S)-nicotine by reduction followed by N-methylation.
...
Process for the Preparation of Advantame :
A novelprocess for the preparation of N-[N-[3-(3-hydroxy-4-methoxyphenyl)-propyl]-L-a-aspartyl]-L-phenylalanine-l-methyl ester is described. It comprises, reacting isovanillin or its derivative with vinyl acétate followed by reductive condensation with L-[a-aspartyl]-L-phe...
A novel process for the preparation of L-threo-dihydroxyphenylserine (Droxidopa) is described. It comprises of enantioselective hydrolysis of racemic (DL)-threo-N-acetyl-3-(3,4-methylenedioxyphenyl)-serine using commercially available L-amino acylase from Aspergillus sp.(EC 3.5.1.14) in the presence of cobalt ions, ...
Process for the Preparation of Vilazodone Hydrochloride and Its Polymorph
A crystalline vilazodone hydrochloride has been prepared by reacting vilazodone free base with trimethylsilyl chloride using isopropanol as the solvent.
The present invention relates to a process for the preparation of 2-butyl-3-[[2"-(1H-tetrazol-5-yl)[1,1"-biphenyl]-4-yl]-l,3-diazaspiro[4,4]non-1-en-4-one by reaction of the corresponding nitrile with sodium azide and piperazine or its acid salt.
This invention discloses Strontium Ranelate polymorph, designated as Form A, having characteristic powdered x-ray diffraction pattern and infrared spectrum with water content of 1.5 to 2.5% and a process for its preparation.
The present invention relates to a novel and improved process for the preparation of linagliptin, chemically known as (R)-8-(3-amino-piperidin-l-yl)-7-but-2-ynyl-3-methyl-l-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione through novel intermediates using (3S)-l-(7-(but-2-ynyl)-3-methyl-l-((4-methylqu...
The present invention relates to an improved process for the preparation of (1S, 3S, 5S)-2-[2(S)-2-amino-2-(3-hydroxy-1-adamantan-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile and its intermediates.
Preparation of 2-(4-Bromophenyl)-2-Methylpropanoic Acid
Selective bromination of 2-methyl-2-phenylpropanoic acid in aqueous medium is described to obtain pure 2-(4-bromophenyl)-2-methylpropanoic acid, which is a useful key intermediate in the process of manufacturing pure fexofenadine.
Process for the Preparation of Rivaroxaban :
A novel process for the preparation of rivaroxaban is described which comprises reacting 4-{4-[(5S)-5-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl] phenyl}-morpho!in-3-one with 5-chIoro thiophene -2-carbonyl chloride using epoxides as non-basic acid scavengers in the presen...
4,1",6"-Trichloro-4,1",6"-trideoxy-galactosucrose-6-acetate undergoes transesterification with alcohols in the presence of catalytic amount of metal oxide to give 4,1",6"-trichloro-4,1",6"-trideoxy-galactosucrose (sucralose) and alkyl acetate. The alkyl acetate formed and the solvent are removed by evaporation and t...
The present invention relates to an improved process for the preparation of N-(4-fluorobenzyl)-N-(l-methy!piperidinyl)-N"-(4-(2-methylpropyloxy)-phenylmethyl carbamide (Formula 1), also known as Pimavanserin, with excellent yield and high degree of chemical purity.
A new method for preparing mono phenyl tenofovir (Formula-I) using diphenyl phosphonate is provided.
Process for the Preparation of Methyl 5-((2,4-difluorobenzyl) carbamoyl) -l-(2,2-dimethoxyethyI)-3-methoxy-4-oxo-l,4-dihydropyridine -2-Carboxylate:
Methyl 5- ((2,4-difluorobenzyl) carbamoyl)-!- (2,2-dimethoxyethyl)-3-methoxy-4-oxo-l,4-dihydropyridine-2-carboxylate is an important intermediate for the preparation o...
A novel crystalline Mirabegron which is a solvate of pentan-3-one is described. It is characterized by IR, XRDand DSC spectrum. The process of its preparation comprises treating Mirabegron with pentan-3-one and spontaneously obtaining the solvate as crystalline solid. The NMR and HPLC analysis of the solvate shows t...
A process for the preparation of 4-iodo-3-nitrobenzamide free from the impurities formed due to nucleophilic substitution of the labile iodo group is disclosed.
The present invention relates to a process for the conversion of gabapentin hydrochloride into gabapentin polymorphic Forms II or III by use of gaseous alkylamine and the choice of a specific solvent.
This invention discloses a process for converting gabapentin acid salt to free gabapentin, where the salt is dissolved in an organic solvent in which both gabapentin acid salt and free gabapentin are soluble. The solution is treated with a powdered alkaline base to liberate free gabapentin which will remain in solut...
Present invention is related to a process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3- methyl-1H-Indole (formula-1, a useful intermediate for the synthesis of bazedoxifene) using 4-benzyloxy propiophenone and 4-benzyloxy phenyl hydrazine hydrochloride.
Enantiomerically pure L-tert-leucine and D-tert-leucine were prepared from (DL)-tert- leucine by diastereomeric salt formation using dibenzoyl-d-tartaric acid as the resolving agent.
A novel process for the preparation of Bazedoxifene acetate and intermediates there of
A novel process is described for the preparation of pharmaceutical useful compounds such as 1 -{4-[2-(azepan-1 –y1)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol acetic acid commonly known as bazedoxifene acetate of fo...
Strontium ranelate is prepared by reacting dicyclohexylammonium ranelate with strontium halide in an anhydrous solvent. Strontium ranelate thus obtained will have less than 3% moisture content.
A process for the preparation of -ionylideneacetaldehyde by oxidizing β-ionylidene ethanol using 2, 2, 6, 6-tetramethylpiperidine-1-oxyl (TEMPO)-ferric chloride is described. Addition of sodium nitrite to the system results in the regeneration of ferric ions, making the whole system catalytic.
The invention disclosed in this application relates to an improved process for the resolution of a racemic mixture of 5-[2-[2-ethoxyphenoxy) ethylamino] propyl]-2-methoxy benzene sulfonamide (tamsulosin) employing BPA either S or R form to obtain enantiomerically hoghly pure R and S-isomer
"Enzymatic Process for the Preparation of (2S)-2-[(4R)-2-oxo-4-propyI pyrrolidine-l-yI]-butyric acid and its conversation into Brivaracetam" :
A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising enzymatic conversion of (2RS)-2-[ (4R)-2-oxo-4-propyl-pyrrolidin-l-yl] butyr...
A process for the preparation of Molnupiravir, an antiviral drug under investigation for the treatment of Covid-19, is provided comprising reacting 2-3-isopropylidene cytidine with isobutyric anhydride in the presence of a base to obtain 5'-isobutyric ester having an amide impurity. Treatingthe reaction mixture with...
A Process For The Preparation Of Brivaracetam From (S) 3 (2 (Chloroamino) 2 Oxoethyl) Hexanoic Acid”
" A Process for Preparing Brivaracetam"
A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising Hofmann rearrangement of (S)-3-(2-(chloroamino)-2-oxoethyl) hexanoic acid, followed by cyclization resulting in (R)-4-propyl-pyrrolidin-2-one which on condensation with bromo butyri...
"Process for the Preparation of Gabapentin"
The invention discloses a new process for the preparation of Gabapentin which comprises the reaction of spiro[cyclohexane-]59"-(3,7-diazabicyclo-[3.3.1]nonane)]-2",4",6!,8"-tetraone (diimide) with an alkali to obtain 1,1-cyclohexane diaceitic acid monoamide (CDMA). CDMA o...
The invention is related to a process for preparing 4-isopropyl cyclohexane earboxylic acid of formula (I) comprising hydrogenating cumic acid of formula (II) in presence of ruthenium catalyst in alkaline aqueous solution followed by acid treatment.
The invention disclosed in this apposition relates to an improved process for the preparation of N,N-dimethyl-3-(4-methyl-benzoyl)-propanolamine from the free acid via its halide by using N,N-dimethylammonium – N1 N1 -dimethyl carbonates, both as a solvent and reagent. The said propionamide is a key interme...
Process for the Preparation of Vilazodone Hydrochloride and Its Polymorph
A crystalline vilazodone hydrochloride has been prepared by reacting vilazodone free base with trimethylsilyl chloride using isopropanol as the solvent.
A process for the preparation of (R)-4-propyl-pyrrolidine-2-one, is provided comprising enzymatic conversion of dimethyl 3-propyl pentanedioate selectively into (S)-3-(2-methoxy-2-oxoethyl) hexanoic acid using Novozyme's Promea® enzyme, amidation of {S)-3-(2-methoxy-2-oxoethyl) hexanoic acid, followed by ester hydro...
" A Novel Process for the Preparation of Valitramiprosate "
A novel and economically viable green process for the preparation of 3-[[(2S)-2-amino-3-methyl-1-oxobutyl] amino]-1-propanesulfonic acid (Formula 1), also known as Valitramiprosate (ALZ-801), with excellent yield and high degree of both chemical and chiral...
Process for the Preparation of FMOC-GLY-THR (PSI (ME, ME) PROJ-OH The present invention describes a process for the preparation of Fmoc-Gly-Thr [Psi (Me, Me) pro]-OH by reacting Fmoc-glycyl chloride with N, O-Bis(trimethylsilyl)-threonine trimethylsilyl ester, in the presence of a base, to obtain Fmoc-Gly-(O-trime...
Registered Trademarks
[Class : 5] Medicinal, Pharmaceutical And Veterinary Preparations.
[Class : 42] Medical And Pharmaceutical Research, Design And Development Services; Pharmaceutical Drug Development Services For Third Parties; The Scientific Research For Medical Services
Charges
27 February 2019
Hdfc Bank Limited
60 Crore
14 December 1995
State Bank Of India
326 Crore
17 October 1996
State Bank Of Hyderabad
55 Crore
12 July 1995
State Bank Of Hyderabad
13 Crore
04 April 1996
State Bank Of Hyderabad (sbh)
42 Crore
08 December 1998
State Bank Of Hyderabad
63 Crore
24 March 1997
State Bank Of Hyderabad
67 Crore
17 October 1996
State Bank Of Hyderabad (sbh)
55 Crore
01 October 1996
State Bank Of Hyderabad
34 Crore
18 September 1995
State Bank Of Hyderabad
22 Crore
19 August 1995
State Bank Of Hyderabad
109 Crore
28 October 2006
The Bank Of Nova Scotia
20 Crore
16 December 1995
The Lakshmi Vilas Bank Limited
3 Crore
16 February 1995
The Lakshmi Vilas Bank Limited
3 Crore
03 October 1996
The Lakshmi Vilas Bank Ltd.
10 Crore
06 October 2005
State Of India
27 Crore
15 June 2006
State Bank Of India - Overseas Branch
50 Crore
28 December 2005
Bank Of Nova Scotia
20 Crore
06 December 2000
Industrial Development Bank Of India (idbi)
5 Crore
17 June 2002
Uti Bank Limited
15 Crore
28 August 2001
Uti Bank Limited
10 Crore
13 December 1999
Idbi Bank Limited
4 Crore
15 November 1995
Industrial Reconstruction Bank Of India
5 Crore
06 March 2000
Industrial Development Bank Of India
5 Crore
26 September 1996
Industrial Development Bank Of India
7 Crore
27 March 1995
Industrial Development Bank Of India
21 Crore
14 December 1995
State Bank Of India
0
27 February 2019
Hdfc Bank Limited
0
27 March 1995
Industrial Development Bank Of India
0
19 August 1995
Others
0
13 December 1999
Idbi Bank Limited
0
18 September 1995
State Bank Of Hyderabad
0
28 October 2006
The Bank Of Nova Scotia
0
17 October 1996
State Bank Of Hyderabad (sbh)
0
06 March 2000
Industrial Development Bank Of India
0
01 October 1996
State Bank Of Hyderabad
0
26 September 1996
Industrial Development Bank Of India
0
16 February 1995
The Lakshmi Vilas Bank Limited
0
15 November 1995
Industrial Reconstruction Bank Of India
0
03 October 1996
The Lakshmi Vilas Bank Ltd.
0
28 August 2001
Uti Bank Limited
0
06 December 2000
Industrial Development Bank Of India (idbi)
0
06 February 2000
Industrial Development Bank Of India
0
08 December 1998
State Bank Of Hyderabad
0
24 March 1997
State Bank Of Hyderabad
0
04 April 1996
State Bank Of Hyderabad (sbh)
0
17 June 2002
Uti Bank Limited
0
12 July 1995
State Bank Of Hyderabad
0
17 October 1996
State Bank Of Hyderabad
0
06 October 2005
State Of India
0
28 December 2005
Bank Of Nova Scotia
0
15 June 2006
State Bank Of India - Overseas Branch
0
16 December 1995
The Lakshmi Vilas Bank Limited
0
14 December 1995
State Bank Of India
0
27 February 2019
Hdfc Bank Limited
0
27 March 1995
Industrial Development Bank Of India
0
19 August 1995
Others
0
13 December 1999
Idbi Bank Limited
0
18 September 1995
State Bank Of Hyderabad
0
28 October 2006
The Bank Of Nova Scotia
0
17 October 1996
State Bank Of Hyderabad (sbh)
0
06 March 2000
Industrial Development Bank Of India
0
01 October 1996
State Bank Of Hyderabad
0
26 September 1996
Industrial Development Bank Of India
0
16 February 1995
The Lakshmi Vilas Bank Limited
0
15 November 1995
Industrial Reconstruction Bank Of India
0
03 October 1996
The Lakshmi Vilas Bank Ltd.
0
28 August 2001
Uti Bank Limited
0
06 December 2000
Industrial Development Bank Of India (idbi)
0
06 February 2000
Industrial Development Bank Of India
0
08 December 1998
State Bank Of Hyderabad
0
24 March 1997
State Bank Of Hyderabad
0
04 April 1996
State Bank Of Hyderabad (sbh)
0
17 June 2002
Uti Bank Limited
0
12 July 1995
State Bank Of Hyderabad
0
17 October 1996
State Bank Of Hyderabad
0
06 October 2005
State Of India
0
28 December 2005
Bank Of Nova Scotia
0
15 June 2006
State Bank Of India - Overseas Branch
0
16 December 1995
The Lakshmi Vilas Bank Limited
0
Documents
Form DPT-3-17052021-signed
Form MGT-6-19122020_signed
-19122020
Form MGT-6-13112020_signed
-13112020
DIVIS-Shareholders-MGT_7_R70774708_VBRAO1234_20201111135826.xlsm
Optional Attachment-(1)-11112020
Copy of MGT-8-11112020
Optional Attachment-(2)-11112020
Form MGT-7-11112020_signed
Form MGT-14-26102020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-26102020
Form AOC-4(XBRL)-26102020-signed
Optional Attachment-(3)-13102020
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-13102020
Optional Attachment-(4)-13102020
XBRL document in respect Consolidated financial statement-13102020
Optional Attachment-(1)-13102020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-13102020
Optional Attachment-(2)-13102020
Optional Attachment-(5)-13102020
Form MGT-6-06102020_signed
-06102020
Form MGT-15-27092020_signed
Form MGT-6-20082020_signed
Form MGT-6-19082020_signed
-19082020
Form MGT-6-11072020_signed
-11072020
Form MGT-6-16062020_signed
